Nestle India refutes media reports of FSSAI legal action, says products comply with regulations

The company said it had submitted a detailed response to FSSAI regarding statements on product labels, asserting that these claims are factual and supported by scientific literature. Nestle India reiterated its adherence to all norms governing product labels and declarations under applicable laws and affirmed its commitment to working with FSSAI on consumer awareness initiatives.

Nestle India confirmed that all material information potentially impacting its operations had been disclosed to stock exchanges in compliance with Regulation 30 of the SEBI Listing Regulations, and that such disclosures had been made regularly, accurately, and timely. In response to the exchange’s query about any undisclosed information that could explain share price movements, the company said it had none to report and added that the news report had no material impact on the company.

Despite Nestle India’s denial, the article notes that FSSAI had initiated three adjudication cases against the company concerning infant nutrition products, specifically NAN Excella and Lactogen. The regulator’s action followed an examination of products and promotional material on e-commerce platforms, where claims such as “5 HMOs” and “Whey Protein” on NAN Excella Pro Stage 1, and the promotion of whey protein as easy to digest in Lactogen Pro 1, were found to breach provisions restricting promotional claims for infant foods under the 2020 regulations and the IMS Act, 1992.

Additionally, testing of a Nestle follow-up formula sample revealed biotin content below the prescribed level, a finding confirmed by a subsequent re-analysis from a referral laboratory. FSSAI stated these results were part of its broader food-safety enforcement efforts and proceeded with three separate adjudication cases based on product and laboratory findings.

The article mentions that Nestle India’s stock settled 1.4% lower at ₹1,353.10 on the Friday following the FSSAI action. Over the past week, the stock declined 3%, and over the last month, it fell 8%. However, over a four-month period, the decline is 4%. In the longer term, the stock remains up 11.5% over six months and 11% over the past year, with a five-year return of 33%.

The stock’s 52-week trading range is between ₹1,145.10 and ₹1,553, having touched the lower end in October 2025 and reached its peak in August 2026. The FSSAI action is significant to consumers due to the nature of infant nutrition products, where accurate composition and regulated claims are critical. The article clarifies that the proceedings should not be seen as a blanket judgment on the safety of all Nestle infant products.

FSSAI has initiated adjudication proceedings, while Nestle India maintains that its products comply with regulations and that the labels in question were approved by an FSSAI expert committee.